MCI-to-normal reversion using neuropsychological criteria in the Alzheimer's Disease Neuroimaging Initiative

Alzheimers Dement. 2019 Oct;15(10):1322-1332. doi: 10.1016/j.jalz.2019.06.4948. Epub 2019 Sep 5.

Abstract

Introduction: The low mild cognitive impairment (MCI) to cognitively normal (CN) reversion rate in the Alzheimer's Disease Neuroimaging Initiative (2-3%) suggests the need to examine reversion by other means. We applied comprehensive neuropsychological criteria (NP criteria) to determine the resulting MCI to CN reversion rate.

Methods: Participants with CN (n = 641) or MCI (n = 569) were classified at baseline and year 1 using NP criteria. Demographic, neuropsychological, and Alzheimer's disease biomarker variables as well as progression to dementia were examined across stable CN, reversion, and stable MCI groups.

Results: NP criteria produced a one-year reversion rate of 15.8%. Reverters had demographics, Alzheimer's disease biomarkers, and risk-of-progression most similar to the stable CN group and showed the most improvement on neuropsychological measures from baseline to year 1.

Discussion: NP criteria produced a reversion rate that is consistent with, albeit modestly improved from, reversion rates in meta-analyses. Reverters' biomarker profiles and progression rates suggest that NP criteria accurately tracked with underlying pathophysiologic status.

Keywords: Alzheimer's disease; Diagnostic criteria; Mild cognitive impairment; Neuropsychology; Reversion; Stability.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Aged
  • Biomarkers
  • Brain / physiopathology
  • Cognition / physiology*
  • Cognitive Dysfunction* / diagnostic imaging
  • Cognitive Dysfunction* / physiopathology
  • Demography
  • Female
  • Humans
  • Neuroimaging*
  • Neuropsychological Tests / statistics & numerical data*

Substances

  • Biomarkers